Nanotechnological carriers for cancer chemotherapy: The state of the art

Colloids and Surfaces B: Biointerfaces

Volumn 126, Issue , 2015, Pages 631-648

  Estanqueiro, Marilene ^a   Amaral, Maria Helena ^a   Conceição, Jaime ^a   Sousa Lobo, José Manuel ^a  

^a UNIVERSITY OF PORTO   (Portugal)

Author keywords

Anticancer drugs; Cancer; Dendrimers; Liposomes; Micelles; Nanoparticles

Indexed keywords

CHEMOTHERAPY; DENDRIMERS; DISEASE CONTROL; DISEASES; DRUG INTERACTIONS; LIPOSOMES; MICELLES; NANOPARTICLES;

ANTIBODY-DRUG CONJUGATES; ANTICANCER DRUG; CANCER; CANCER CHEMOTHERAPY; LIPID NANOPARTICLES; PARTICULATE SYSTEMS; SCIENCE AND TECHNOLOGY; WORLD HEALTH ORGANIZATION;

CONTROLLED DRUG DELIVERY;

ALBUMIN NANOPARTICLE; BUSULFAN; CARBOXYMETHYLCELLULOSE; CYSTEINE; DENDRIMER; DOXORUBICIN; ETHOSOME; LANTHANIDE OXIDE NANOPARTICLE; LIPOSOME; MACROGOL; MANGANESE DOPED ZINC SULFIDE QUANTUM DOT; N (2 HYDROXYPROPYL)METHACRYLAMIDE; NANOCARRIER; NANOSTRUCTURED LIPID CARRIER; NIOSOME; PHOSPHOLIPID; POLYACRYLIC ACID; POLYGLACTIN; POLYGLUTAMIC ACID; PROTEIN NANOPARTICLE; QUANTUM DOT; SOLID LIPID NANOPARTICLE; SUPERPARAMAGNETIC IRON OXIDE NANOPARTICLE; TRANSFERSOME; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; DRUG CARRIER;

CANCER CHEMOTHERAPY; DRUG DELIVERY SYSTEM; HUMAN; IN VITRO STUDY; IN VIVO STUDY; NANOTECHNOLOGY; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; RECEPTOR BINDING; REVIEW; ANIMAL; CHEMISTRY; NANOMEDICINE; NEOPLASMS;

ANIMALS; ANTINEOPLASTIC AGENTS; DRUG CARRIERS; HUMANS; NANOMEDICINE; NEOPLASMS;

EID: 84923065229     PISSN: 09277765     EISSN: 18734367     Source Type: Journal    
DOI: 10.1016/j.colsurfb.2014.12.041     Document Type: Review

References (269)

1. Defining Cancer National Cancer Institute at the National Institutes of Health 2013, Available from: http://www.cancer.gov/cancertopics/cancerlibrary/what-is-cancer (accessed 02.12.13).
2. Sinha R., Kim G.J., Nie S., Shin D.M. Nanotechnology in cancer therapeutics: bioconjugated nanoparticles for drug delivery. Mol. Cancer Ther. 2006, 5:1909-1917.
3. Balaji S., Devi B.P. Nanotecnology and cancer - an overview. Int. J. Pharma BioSci. 2010, 1:186-201.
4. Zuidam N.J., Gouw H.K.M.E., Barenholz Y., Crommelin D.J.A. Physical (in) stability of liposomes upon chemical hydrolysis: the role of lysophospholipids and fatty acids. BBA: Biomembr. 1995, 1240:101-110.
5. Ferlay J., Soerjomataram I., Ervik M., Dikshit R., Eser S., Mathers C., Rebelo M., Parkin D.M., Forman D., Bray F. GLOBOCAN 2012 v1.0, Cancer Incidence and Mortality Worldwide: IARC Cancer Base No. 11 [Internet] 2013, International Agency for Research on Cancer, Lyon, France, Available from: http://globocan.iarc.fr (accessed 13.05.14).
6. Brizel D.M., Albers M.E., Fisher S.R., Scher R.L., Richtsmeier W.J., Hars V., George S.L., Huang A.T., Prosnitz L.R. Hyperfractionated irradiation with or without concurrent chemotherapy for locally advanced head and neck cancer. N. Engl. J. Med. 1998, 338:1798-1804.
7. Chemotherapy Principles American Cancer Society 2013, Available from: http://www.cancer.org/treatment/treatmentsandsideeffects/treatmenttypes/chemotherapy/chemotherapyprinciplesanin-depthdiscussionofthetechniquesanditsroleintreatment/chemotherapy-principles-indepth-toc (accessed 27.02.14).
8. Chu E., Devita V.T. Principles of cancer management: chemotherapy. Cancer: Principles and Practice of Oncology 2001, 224-235. Lippincott Williams & Wilkins Publishers, Philadelphia. V.T. Devita, S. Hellman, S.A. Rosenberg (Eds.).
9. Different Types of Chemotherapy Drugs American Cancer Society 2013, Available from: http://www.cancer.org/treatmentsandsideeffects/treatmenttypes/chemotherapy/chemotherapyprinciplesanin-depthdiscussionofthetechniquesanditsroleintreatment/chemotherapy-principles-types-of-chemo-drugs (accessed 26.02.14).
10. Colvin O.M. Antitumor alkylating agents. Cancer: Principles and Practice of Oncology 2001, 278-288. Lippincott Williams & Wilkins Publishers, Philadelphia. V.T. Devita, S. Hellman, S.A. Rosenberg (Eds.).
11. Chu E., Mota A.C., Fogarasi M.C. Antimetabolites. Cancer: Principles and Practice of Oncology 2001, 298-317. Lippincott Williams & Wilkins Publishers, Philadelphia. V.T. Devita, S. Hellman, S.A. Rosenberg (Eds.).
12. Stewart C.F., Ratain M.J. Topoisomerase interactive agents. Cancer: Principles and Practice of Oncology 2001, 318-328. Lippincott Williams & Wilkins Publishers, Philadelphia. V.T. Devita, S. Hellman, S.A. Rosenberg (Eds.).
13. Rowinsky E.K., Tolcher A.W. Antimicrotubule agents. Cancer: Principles and Practice of Oncology 2001, 329-344. Lippincott Williams & Wilkins Publishers, Philadelphia. V.T. Devita, S. Hellman, S.A. Rosenberg (Eds.).
14. Cheson B.D. Miscellaneous chemotherapeutic agents. Cancer: Principles and Practice of Oncology 2001, 345-350. Lippincott Williams & Wilkins Publishers, Philadelphia. V.T. Devita, S. Hellman, S.A. Rosenberg (Eds.).
15. Modolell M., Andreesen R., Pahlke W., Brugger U., Munder P.G. Disturbance of phospholipid metabolism during the selective destruction of tumor cells induced by alkyl-lysophospholipids. Cancer Res. 1979, 39:4681-4686.
16. Herrmann D.B.J. Changes in cellular lipid synthesis of normal and neoplastic cells during cytolysis induced by alkyl lysophospholipid analogues. J. Natl. Cancer Inst. 1985, 75:423-430.
17. Ruiter G.A., Verheij M., Zerp S.F., van Blitterswijk W.J. Alkyl-lysophospholipids as anticancer agents and enhancers of radiation-induced apoptosis. Int. J. Radiat. Oncol. Biol. Phys. 2001, 49:415-419.
18. Chaplin D.J., Hill S.A., Bell K.M., Tozer G.M. Modification of tumor blood flow: current status and future directions. Semin. Radiat. Oncol. 1998, 8:151-163.
19. Needham D., Dewhirst M.W. The development and testing of a new temperature-sensitive drug delivery system for the treatment of solid tumors. Adv. Drug Deliv. Rev. 2001, 53:285-305.
20. Jain R.K. Barriers to drug delivery in solid tumors. Sci. Am. 1994, 271:58-65.
21. Yuan F. Transvascular drug delivery in solid tumors. Semin. Radiat. Oncol. 1998, 8:164-175.
22. Dancey J., Eisenhauer E.A. Current perspectives on camptothecins in cancer treatment. Br. J. Cancer 1996, 74:327-338.
23. Slichenmyer W.J., Rowinsky E.K., Donehower R.C., Kaufmann S.H. The current status of camptothecin analogues as antitumor agents. J. Natl. Cancer Inst. 1993, 85:271-291.
24. Muggia F.M., Creaven P.J., Hansen H.H., Cohen M.H., Selawry O.S. Phase I clinical trial of weekly and daily treatment with camptothecin (NSC-100880): correlation with preclinical studies. Cancer Chemother. Rep. 1972, 56:515-521.
25. Matsumura Y., Maeda H. A new concept for macromolecular therapeutics in cancer chemotherapy: mechanism of tumoritropic accumulation of proteins and the antitumor agent smancs. Cancer Res. 1986, 46:6387-6392.
26. Strickley R.G. Solubilizing excipients in oral and injectable formulations. Pharm. Res. 2004, 21:201-230.
27. Yao X., Panichpisal K., Kurtzman N., Nugent K. Cisplatin nephrotoxicity: a review. Am. J. Med. Sci. 2007, 334:115-124.
28. Ekborn A., Laurell G., Johnström P., Wallin I., Eksborg S., Ehrsson H. d-Methionine and cisplatin ototoxicity in the guinea pig: d-methionine influences cisplatin pharmacokinetics. Hear. Res. 2002, 165:53-61.
29. Gamelin E.C., Danquechin-Dorval E.M., Dumesnil Y.F., Maillart P.J., Goudier M.J., Burtin P.C., Delva R.G., Lortholary A.H., Gesta P.H., Larra F.G. Relationship between 5-fluorouracil (5-FU) dose intensity and therapeutic response in patients with advanced colorectal cancer receiving infusional therapy containing 5-FU. Cancer 1996, 77:441-451.
30. Sorrentino M.F., Kim J., Foderaro A.E., Truesdell A.G. 5-Fluorouracil induced cardiotoxicity: review of the literature. Cardiol. J. 2012, 19:453-458.
31. Weiss R.B. Hypersensitivity reactions from taxol. J. Clin. Oncol. 1990, 8:1263-1268.
32. Needham D. Materials engineering of lipid bilayers for drug carrier performance. MRS Bull. 1999, 24:32-41.
33. Aderem A., Underhill D.M. Mechanisms of phagocytosis in macrophages. Annu. Rev. Immunol. 1999, 17:593-623.
34. Saba T.M. Physiology and physiopathology of the reticuloendothelial system. Arch. Intern. Med. 1970, 126:1031-1052.
35. Yoo J.W., Doshi N., Mitragotri S. Adaptive micro and nanoparticles: temporal control over carrier properties to facilitate drug delivery. Adv. Drug Deliv. Rev. 2011, 63:1247-1256.
36. Moghimi S.M., Hunter A.C., Murray J.C. Long-circulating and target-specific nanoparticles: theory to practice. Pharmacol. Rev. 2001, 53:283-318.
37. Rejman J., Oberle V., Zuhorn I.S., Hoekstra D. Size-dependent internalization of particles via the pathways of clathrin- and caveolae-mediated endocytosis. Biochem. J. 2004, 377:159-169.
38. Laverman P., Boerman O.C., Oyen W.J.G., Dams E.T.M., Storm G., Corstens F.H.M. Liposomes for scintigraphic detection of infection and inflammation. Adv. Drug Deliv. Rev. 1999, 37:225-235.
39. Decuzzi P., Pasqualini R., Arap W., Ferrari M. Intravascular delivery of particulate systems: does geometry really matter?. Pharm. Res. 2009, 26:235-243.
40. Yoo J.W., Chambers E., Mitragotri S. Factors that control the circulation time of nanoparticles in blood: challenges, solutions and future prospects. Curr. Pharm. Des. 2010, 16:2298-2307.
41. Hong R.L., Huang C.J., Tseng Y.L., Pang V.F., Chen S.T., Liu J.J., Chang F.H. Direct comparison of liposomal doxorubicin with or without polyethylene glycol coating in C-26 tumor-bearing mice: is surface coating with polyethylene glycol beneficial?. Clin. Cancer Res. 1999, 5:3645-3652.
42. Doshi N., Zahr A.S., Bhaskar S., Lahann J., Mitragotri S. Red blood cell-mimicking synthetic biomaterial particles. Proc. Natl. Acad. Sci. U. S. A. 2009, 106:21495-21499.
43. Yoo J.W., Doshi N., Mitragotri S. Endocytosis and intracellular distribution of PLGA particles in endothelial cells: effect of particle geometry. Macromol. Rapid Commun. 2010, 31:142-148.
44. Geng Y., Dalhaimer P., Cai S., Tsai R., Tewari M., Minko T., Discher D.E. Shape effects of filaments versus spherical particles in flow and drug delivery. Nat. Nanotechnol. 2007, 2:249-255.
45. Beningo K.A., Wang Y.-L. Fc-receptor-mediated phagocytosis is regulated by mechanical properties of the target. J. Cell Sci. 2002, 115:849-856.
46. Fang J., Nakamura H., Maeda H. The EPR effect: unique features of tumor blood vessels for drug delivery, factors involved, and limitations and augmentation of the effect. Adv. Drug Deliv. Rev. 2011, 63:136-151.
47. Cabral H., Matsumoto Y., Mizuno K., Chen Q., Murakami M., Kimura M., Terada Y., Kano M.R., Miyazono K., Uesaka M., Nishiyama N., Kataoka K. Accumulation of sub-100nm polymeric micelles in poorly permeable tumours depends on size. Nat. Nanotechnol. 2011, 6:815-823.
48. Cho K., Wang X., Nie S., Chen Z.G., Shin D.M. Therapeutic nanoparticles for drug delivery in cancer. Clin. Cancer Res. 2008, 14:1310-1316.
49. de Oliveira A.M., Jäger E., Jäger A., Stepánek P., Giacomelli F.C. Physicochemical aspects behind the size of biodegradable polymericnanoparticles: a step forward. Adv. Colloid Interface Sci. 2013, 436:1092-1102.
50. Marianecci C., Di Marzio L., Rinaldi F., Celia C., Paolino D., Alhaique F., Esposito S., Carafa M. Niosomes from 80s to present: the state of the art. Adv. Colloid Interface Sci. 2014, 205:187-206.
51. Pradhan M., Singh D., Singh M.R. Novel colloidal carriers for psoriasis: current issues, mechanistic insight and novel delivery approaches. J. Control. Release 2013, 170:380-395.
52. Allen T.M. Liposomes: opportunities in drug delivery. Drugs 1997, 54:8-14.
53. Vemuri S., Rhodes C.T. Preparation and characterization of liposomes as therapeutic delivery systems: a review. Pharm. Acta Helv. 1995, 70:95-111.
54. Mozafari R. Liposomes: an overview of manufacturing techniques. Cell. Mol. Biol. Lett. 2005, 10:711-719.
55. Wagner A., Vorauer-Uhl K., Katinger H. Liposomes produced in a pilot scale: production, purification and efficiency aspects. Eur. J. Pharm. Biopharm. 2002, 54:213-219.
56. Sandip B.T., Udupa N., Rao B.S.S., Devi P.U. Thermosensitive liposomes and localised hyperthermia - an effective bimodality approach for tumour management. Indian J. Pharmacol. 2000, 32:214-220.
57. Edwards K.A., Baeumner A.J. Liposomes in analyses. Talanta 2006, 68:1421-1431.
58. Torchilin V.P. Recent advances with liposomes as pharmaceutical carriers. Nat. Rev. Drug Discov. 2005, 4:145-160.
59. Ferrari M. Cancer nanotechnology: opportunities and challenges. Nat. Rev. Cancer 2005, 5:161-171.
60. Park J. Liposome-based drug delivery in breast cancer treatment. Breast Cancer Res. 2002, 4:95-99.
61. Drummond D.C., Noble C.O., Hayes M.E., Park J.W., Kirpotin D.B. Pharmacokinetics and in vivo drug release rates in liposomal nanocarrier development. J. Pharm. Sci. 2008, 97:4696-4740.
62. Moutinho C., Matos C., Balcão V. Development of innovative nanotechnology-based drug delivery systems for cancer therapy. Revista FCS-UFP 2007, 4:94-104.
63. Oberoi H.S., Nukolova N.V., Kabanov A.V., Bronich T.K. Nanocarriers for delivery of platinum anticancer drugs. Adv. Drug Deliv. Rev. 2013, 65:1667-1685.
64. Maruyama K., Ishida O., Takizawa T., Moribe K. Possibility of active targeting to tumor tissues with liposomes. Adv. Drug Deliv. Rev. 1999, 40:89-102.
65. Wu N.Z., Da D., Rudoll T.L., Needham D., Whorton A.R., Dewhirst M.W. Increased microvascular permeability contributes to preferential accumulation of Stealth liposomes in tumor tissue. Cancer Res. 1993, 53:3765-3770.
66. Gabizon A.A. Stealth liposomes and tumor targeting: one step further in the quest for the magic bullet. Clin. Cancer Res. 2001, 7:223-225.
67. O'Shaughnessy J.A. Pegylated liposomal doxorubicin in the treatment of breast cancer. Clin. Breast Cancer 2003, 4:318-328.
68. Gabizon A.A. Pegylated liposomal doxorubicin: metamorphosis of an old drug into a new form of chemotherapy. Cancer Invest. 2001, 19:424-436.
69. Torchilin V.P., Klibanov A.L., Huang L., O'Donnell S., Nossiff N.D., Khaw B.A. Targeted accumulation of polyethylene glycol-coated immunoliposomes in infarcted rabbit myocardium. FASEB J. 1992, 6:2716-2719.
70. Torchilin V.P. Immunoliposomes and PEGylated immunoliposomes: possible use for targeted delivery of imaging agents. ImmunoMethods 1994, 4:244-258.
71. Torchilin V.P., Narula J., Halpern E., Khaw B.A. Poly(ethylene glycol)-coated anti-cardiac myosin immunoliposomes: factors influencing targeted accumulation in the infarcted myocardium. BBA: Biomembr. 1996, 1279:75-83.
72. Yatvin M.B., Weinstein J.N., Dennis W.H., Blumenthal R. Design of liposomes for enhanced local release of drugs by hyperthermia. Science 1978, 202:1290-1293.
73. Kong G., Anyarambhatla G., Petros W.P., Braun R.D., Colvin O.M., Needham D., Dewhirst M.W. Efficacy of liposomes and hyperthermia in a human tumor xenograft model: importance of triggered drug release. Cancer Res. 2000, 60:6950-6957.
74. Gaber M.H., Wu N.Z., Hong K., Huang S.K., Dewhirst M.W., Papahadjopoulos D. Thermosensitive liposomes: extravasation and release of contents in tumor microvascular networks. Int. J. Radiat. Oncol. Biol. Phys. 1996, 36:1177-1187.
75. Zhu L., Huo Z., Wang L., Tong X., Xiao Y., Ni K. Targeted delivery of methotrexate to skeletal muscular tissue by thermosensitive magnetoliposomes. Int. J. Pharm. 2009, 370:136-143.
76. Koshkaryev A., Sawant R., Deshpande M., Torchilin V. Immunoconjugates and long circulating systems: origins, current state of the art and future directions. Adv. Drug Deliv. Rev. 2013, 65:24-35.
77. Uchegbu I.F., Florence A.T. Non-ionic surfactant vesicles (niosomes): physical and pharmaceutical chemistry. Adv. Colloid Interface Sci. 1995, 58:1-55.
78. Farkas E., Schubert R., Zelkó R. Effect of β-sitosterol on the characteristics of vesicular gels containing chlorhexidine. Int. J. Pharm. 2004, 278:63-70.
79. Mahale N.B., Thakkar P.D., Mali R.G., Walunj D.R., Chaudhari S.R. Niosomes: novel sustained release nonionic stable vesicular systems - an overview. Adv. Colloid Interface Sci. 2012, 183-184:46-54.
80. Jiao J. Polyoxyethylated nonionic surfactants and their applications in topical ocular drug delivery. Adv. Drug Deliv. Rev. 2008, 60:1663-1673.
81. Kumar G.P., Rajeshwarrao P. Nonionic surfactant vesicular systems for effective drug delivery - an overview. Acta Pharm. Sin. B 2011, 1:208-219.
82. Kong M., Park H., Feng C., Hou L., Cheng X., Chen X. Construction of hyaluronic acid noisome as functional transdermal nanocarrier for tumor therapy. Carbohydr. Polym. 2013, 94:634-641.
83. Tavano L., Vivacqua M., Carito V., Muzzalupo R., Caroleo M.C., Nicoletta F. Doxorubicin loaded magneto-niosomes for targeted drug delivery. Colloids Surf. B: Biointerfaces 2013, 102:803-807.
84. Cevc G., Blume G. Lipid vesicles penetrate into intact skin owing to the transdermal osmotic gradients and hydration force. BBA: Biomembr. 1992, 1104:226-232.
85. Honeywell-Nguyen P.L., Bouwstra J.A. Vesicles as a tool for transdermal and dermal delivery. Drug Discov. Today Technol. 2005, 2:67-74.
86. Trotta M., Peira E., Carlotti M.E., Gallarate M. Deformable liposomes for dermal administration of methotrexate. Int. J. Pharm. 2004, 270:119-125.
87. El Maghraby G.M.M., Williams A.C., Barry B.W. Oestradiol skin delivery from ultradeformable liposomes: refinement of surfactant concentration. Int. J. Pharm. 2000, 196:63-74.
88. Cevc G. Transfersomes, liposomes and other lipid suspensions on the skin: permeation enhancement, vesicle penetration, and transdermal drug delivery. Crit. Rev. Ther. Drug Carrier Syst. 1996, 13:257-388.
89. El Maghraby G.M.M., Williams A.C., Barry B.W. Skin delivery of oestradiol from deformable and traditional liposomes: mechanistic studies. J. Pharm. Pharmacol. 1999, 51:1123-1134.
90. Cevc G., Schätzlein A., Richardsen H. Ultradeformable lipid vesicles can penetrate the skin and other semi-permeable barriers unfragmented. Evidence from double label CLSM experiments and direct size measurements. BBA: Biomembr. 2002, 1564:21-30.
91. Lau K.G., Chopra S., Maitani Y. Entrapment of bleomycin in ultra-deformable liposomes. STP Pharma Sci. 2003, 13:237-239.
92. Lau K.G., Hattori Y., Chopra S., O'Toole E.A., Storey A., Nagai T., Maitani Y. Ultra-deformable liposomes containing bleomycin: in vitro stability and toxicity on human cutaneous keratinocyte cell lines. Int. J. Pharma 2005, 300:4-12.
93. El Maghraby G.M.M., Williams A.C., Barry B.W. Skin delivery of 5-fluorouracil from ultradeformable and standard liposomes in-vitro. J. Pharm. Pharmacol. 2001, 53:1069-1077.
94. Hiruta Y., Hattori Y., Kawano K., Obata Y., Maitani Y. Novel ultra-deformable vesicles entrapped with bleomycin and enhanced to penetrate rat skin. J. Control. Release 2006, 113:146-154.
95. Maheshwari R.G.S., Tekade R.K., Sharma P.A., Darwhekar G., Tyagi A., Patel R.P., Jain D.K. Ethosomes and ultradeformable liposomes for transdermal delivery of clotrimazole: a comparative assessment. Saudi Pharm. J. 2012, 20:161-170.
96. Berner B., Liu P. Alcohols. Percutaneous Penetration Enhancers 1995, 45-60. CRC Press, Boca Raton. E.W. Smith, H.I. Maibach (Eds.).
97. Merdan V., Alhaique F., Touitou E. Vesicular carriers for topical delivery. Acta Technol. Leg. Med. 1998, 12:1-6.
98. Barry B.W. Is transdermal drug delivery research still important today?. Drug Discov. Today 2001, 6:967-971.
99. ®: potential treatment of squamous cell carcinoma, a malignant transformation of actinic keratoses. Eur. J. Pharm. Biopharm. 2012, 81:102-112.
100. Pardeike J., Hommoss A., Müller R.H. Lipid nanoparticles (SLN, NLC) in cosmetic and pharmaceutical dermal products. Int. J. Pharm. 2009, 366:170-184.
101. Müller R.H., Mäder K., Gohla S. Solid lipid nanoparticles (SLN) for controlled drug delivery - a review of the state of the art. Eur. J. Pharm. Biopharm. 2000, 50:161-177.
102. J.S. Lucks, R.H. Müller (Inventors), Medication Vehicles Made of Solid Lipid Particles (Solid Lipid Nanospheres SLN), 1991.
103. ®) for controlled drug delivery. Submicron Emulsions in Drug Targeting and Delivery 1998, 219-234. Harwood Academic Publishers, Amsterdam. S. Benite (Ed.).
104. Teeranachaideekul V., Souto E.B., Junyaprasert V.B., Müller R.H. Cetyl palmitate-based NLC for topical delivery of Coenzyme Q10 - development, physicochemical characterization and in vitro release studies. Eur. J. Pharm. Biopharm. 2007, 67:141-148.
105. Müller R.H., Radtke M., Wissing S.A. Solid lipid nanoparticles (SLN) and nanostructured lipid carriers (NLC) in cosmetic and dermatological preparations. Adv. Drug Deliv. Rev. 2002, 54:S131-S155.
106. Souto E.B., Wissing S.A., Barbosa C.M., Müller R.H. Development of a controlled release formulation based on SLN and NLC for topical clotrimazole delivery. Int. J. Pharm. 2004, 278:71-77.
107. Pouton C.W. Lipid formulations for oral administration of drugs: non-emulsifying, self-emulsifying and 'self-microemulsifying' drug delivery systems. Eur. J. Pharm. Sci. 2000, 11:S93-S98.
108. Jores K., Mehnert W., Drechsler M., Bunjes H., Johann C., Mäder K. Investigations on the structure of solid lipid nanoparticles (SLN) and oil-loaded solid lipid nanoparticles by photon correlation spectroscopy, field-flow fractionation and transmission electron microscopy. J. Control. Release 2004, 95:217-227.
109. Lippacher A., Müller R.H., Mäder K. Investigation on the viscoelastic properties of lipid based colloidal drug carriers. Int. J. Pharm. 2000, 196:227-230.
110. Athawale R.B., Jain D.S., Singh K.K., Gude R.P. Etoposide loaded solid lipid nanoparticles for curtailing B16F10 melanoma colonization in lung. Biomed. Pharmacother. 2014, 68:231-240.
111. Wang P., Zhang L., Peng H., Li Y., Xiong J., Xu Z. The formulation and delivery of curcumin with solid lipid nanoparticles for the treatment of on non-small cell lung cancer both in vitro and in vivo. Mater. Sci. Eng. C: Mater. Biol. Appl. 2013, 33:4802-4808.
112. Aznar M.Á., Lasa-Saracíbar B., Estella-Hermoso de Mendoza A., Blanco-Prieto M.J. Efficacy of edelfosine lipid nanoparticles in breast cancer cells. Int. J. Pharm. 2013, 454:720-726.
113. Lasa-Saracíbar B., Aznar M.Á., Lana H., Aizpún I., Gil A.G., Blanco-Prieto M.J. Lipid nanoparticles protect from edelfosine toxicity in vivo. Int. J. Pharm. 2014, 474:1-5.
114. Miao J., Du Y.-Z., Yuan H., Zhang X.-G., Hu F.-Q. Drug resistance reversal activity of anticancer drug loaded solid lipid nanoparticles in multi-drug resistant cancer cells. Colloids Surf. B: Biointerfaces 2013, 110:74-80.
115. Yang X.-Y., Li Y.-X., Li M., Zhang L., Feng L.-X., Zhang N. Hyaluronic acid-coated nanostructured lipid carriers for targeting paclitaxel to cancer. Cancer Lett. 2013, 334:338-345.
116. Taratula O., Kuzmov A., Shah M., Garbuzenko O.B., Minko T. Nanostructured lipid carriers as multifunctional nanomedicine platform for pulmonary co-delivery of anticancer drugs and siRNA. J. Control. Release 2013, 171:349-357.
117. Bae Y., Kataoka K. Intelligent polymeric micelles from functional poly(ethylene glycol)-poly(amino acid) block copolymers. Adv. Drug Deliv. Rev. 2009, 61:768-784.
118. Torchilin V.P. Structure and design of polymeric surfactant-based drug delivery systems. J. Control. Release 2001, 73:137-172.
119. Tyrrell Z.L., Shen Y., Radosz M. Fabrication of micellar nanoparticles for drug delivery through the self-assembly of block copolymers. Prog. Polym. Sci. 2010, 35:1128-1143.
120. Shuai X., Ai H., Nasongkla N., Kim S., Gao J. Micellar carriers based on block copolymers of poly(e{open}-caprolactone) and poly(ethylene glycol) for doxorubicin delivery. J. Control. Release 2004, 98:415-426.
121. Lin W., He Y., Zhang J., Wang L., Wang Z., Ji F., Chen S. Highly hemocompatible zwitterionic micelles stabilized by reversible cross-linkage for anti-cancer drug delivery. Colloids Surf. B: Biointerfaces 2014, 115:384-390.
122. Sawant R.R., Torchilin V.P. Multifunctionality of lipid-core micelles for drug delivery and tumour targeting. Mol. Membr. Biol. 2010, 27:232-246.
123. Torchilin V.P. PEG-based micelles as carriers of contrast agents for different imaging modalities. Adv. Drug Deliv. Rev. 2002, 54:235-252.
124. Torchilin V.P., Lukyanov A.N., Gao Z., Papahadjopoulos-Sternberg B. Immunomicelles: targeted pharmaceutical carriers for poorly soluble drugs. Proc. Natl. Acad. Sci. U. S. A. 2003, 100:6039-6044.
125. Jin C., Qian N., Zhao W., Yang W., Bai L., Wu H., Wang M., Song W., Dou K. Improved therapeutic effect of DOX-PLGA-PEG micelles decorated with bivalent fragment HAb18 F(ab')2 for hepatocellular carcinoma. Biomacromolecules 2010, 11:2422-2431.
126. Groneberg D.A., Giersig M., Welte T., Pison U. Nanoparticle-based diagnosis and therapy. Curr. Drug Targets 2006, 7:643-648.
127. Torchilin V.P. Lipid-core micelles for targeted drug delivery. Curr. Drug Deliv. 2005, 2:319-327.
128. ® F127-poly (methyl vinyl ether-alt-maleic acid) copolymer and production of its micelles for doxorubicin delivery in breast cancer. Chem. Eng. 2014, 240:133-146.
129. Wang J., Yang G., Guo X., Tang Z., Zhong Z., Zhou S. Redox-responsive polyanhydride micelles for cancer therapy. Biomaterials 2014, 35:3080-3090.
130. Abouzeid A.H., Patel N.R., Torchilin V.P. Polyethylene glycol-phosphatidylethanolamine (PEG-PE)/vitamin E micelles for co-delivery of paclitaxel and curcumin to overcome multi-drug resistance in ovarian cancer. Int. J. Pharm. 2014, 464:178-184.
131. Ke X.-Y., Lin Ng V.W., Gao S.-J., Tong Y.W., Hedrick J.L., Yang Y.Y. Co-delivery of thioridazine and doxorubicin using polymeric micelles for targeting both cancer cells and cancer stem cells. Biomaterials 2014, 35:1096-1108.
132. Salzano G., Riehle R., Navarro G., Perche F., De Rosa G., Torchilin V.P. Polymeric micelles containing reversibly phospholipid-modified anti-survivin siRNA: a promising strategy to overcome drug resistance in cancer. Cancer Lett. 2014, 343:224-231.
133. Lee E.S., Gao Z., Kim D., Park K., Kwon I.C., Bae Y.H. Super pH-sensitive multifunctional polymeric micelle for tumor pHe specific TAT exposure and multidrug resistance. J. Control. Release 2008, 129:228-236.
134. Tomalia D.A., Banker H., Dewald J., Hall M., Kallos G., Martin S., Roeck J., Ryder J. A new class of polymers: starburst-dendritic macromolecules. Polym. J. 1985, 17:117.
135. Newkome G.R., Yao Z.Q., Baker G.R., Gupta V.K. Cascade molecules: a new approach to micelles. A [27]-arborol. J. Org. Chem. 1985, 50:2003-2004.
136. Gillies E.R., Fréchet J.M.J. Dendrimers and dendritic polymers in drug delivery. Drug Discov. Today 2005, 10:35-43.
137. Cheng Y., Xu Z., Ma M., Xu T. Dendrimers as drug carriers: applications in different routes of drug administration. J. Pharm. Sci. 2008, 97:123-143.
138. Thanki K., Gangwal R.P., Sangamwar A.T., Jain S. Oral delivery of anticancer drugs: challenges and opportunities. J. Control. Release 2013, 170:15-40.
139. Svenson S. Dendrimers as versatile platform in drug delivery applications. Eur. J. Pharm. Biopharm. 2009, 71:445-462.
140. Jain K., Kesharwani P., Gupta U., Jain N.K. Dendrimer toxicity: let's meet the challenge. Int. J. Pharm. 2010, 394:122-142.
141. Duncan R., Izzo L. Dendrimer biocompatibility and toxicity. Adv. Drug Deliv. Rev. 2005, 57:2215-2237.
142. Smith P.E.S., Brender J.R., Dürr U.H.N., Xu J., Mullen D.G., Banaszak Holl M.M., Ramamoorthy A. Solid-state NMR reveals the hydrophobic-core location of poly(amidoamine) dendrimers in biomembranes. J. Am. Chem. Soc. 2010, 132:8087-8097.
143. Dufès C., Uchegbu I.F., Schätzlein A.G. Dendrimers in gene delivery. Adv. Drug Deliv. Rev. 2005, 57:2177-2202.
144. Cheng Y., Zhao L., Li Y., Xu T. Design of biocompatible dendrimers for cancer diagnosis and therapy: current status and future perspectives. Chem. Soc. Rev. 2011, 40:2673-2703.
145. Tomalia D.A. Birth of a new macromolecular architecture: dendrimers as quantized building blocks for nanoscale synthetic polymer chemistry. Prog. Polym. Sci. 2005, 30:294-324.
146. Gupta U., Agashe H.B., Asthana A., Jain N.K. Dendrimers: novel polymeric nanoarchitectures for solubility enhancement. Biomacromolecules 2006, 7:649-658.
147. Li Y., Cheng Y., Xu T. Design, synthesis and potent pharmaceutical applications of glycodendrimers: a mini review. Curr. Drug Discov. Technol. 2007, 4:246-254.
148. D'Emanuele A., Attwood D. Dendrimer-drug interactions. Adv. Drug Deliv. Rev. 2005, 57:2147-2162.
149. Bhadra D., Bhadra S., Jain S., Jain N.K. A PEGylated dendritic nanoparticulate carrier of fluorouracil. Int. J. Pharm. 2003, 257:111-124.
150. Kojima C., Kono K., Maruyama K., Takagishi T. Synthesis of polyamidoamine dendrimers having poly(ethylene glycol) grafts and their ability to encapsulate anticancer drugs. Bioconjug. Chem. 2000, 11:910-917.
151. Gillies E.R., Jonsson T.B., Fréchet J.M.J. Stimuli-responsive supramolecular assemblies of linear-dendritic copolymers. J. Am. Chem. Soc. 2004, 126:11936-11943.
152. Malik N., Evagorou E.G., Duncan R. Dendrimer-platinate: a novel approach to cancer chemotherapy. Anticancer Drugs 1999, 10:767-776.
153. Sadekar S., Thiagarajan G., Bartlett K., Hubbard D., Ray A., McGill L.D., Ghandehari H. Poly(amido amine) dendrimers as absorption enhancers for oral delivery of camptothecin. Int. J. Pharm. 2013, 456:175-185.
154. Kumari A., Yadav S.K., Yadav S.C. Biodegradable polymeric nanoparticles based drug delivery systems. Int. J. Pharm. 2010, 75:1-18.
155. Hans M.L., Lowman A.M. Biodegradable nanoparticles for drug delivery and targeting. Curr. Opin. Solid State Mater. Sci. 2002, 6:319-327.
156. Soppimath K.S., Aminabhavi T.M., Kulkarni A.R., Rudzinski W.E. Biodegradable polymeric nanoparticles as drug delivery devices. J. Control. Release 2001, 70:1-20.
157. Panyam J., Zhou W.Z., Prabha S., Sahoo S.K., Labhasetwar V. Rapid endo-lysosomal escape of poly(dl-lactide-co-glycolide) nanoparticles: Implications for drug and gene delivery. FASEB J. 2002, 16:1217-1226.
158. Nobs L., Buchegger F., Gurny R., Allémann E. Poly(lactic acid) nanoparticles labeled with biologically active Neutravidin™ for active targeting. Eur. J. Pharm. Biopharm. 2004, 58:483-490.
159. Ikezoe T., Yang Y., Bandobashi K., Saito T., Takemoto S., Machida H., Togitani K., Koeffler H.P., Taguchi H. Oridonin, a diterpenoid purified from Rabdosia rubescens, inhibits the proliferation of cells from lymphoid malignancies in association with blockade of the NF-κB signal pathways. Mol. Cancer Ther. 2005, 4:578-586.
160. Xing J., Zhang D., Tan T. Studies on the oridonin-loaded poly(d,l-lactic acid) nanoparticles in vitro and in vivo. Int. J. Biol. Macromol. 2007, 40:153-158.
161. Shenoy D.B., Amiji M.M. Poly(ethylene oxide)-modified poly(e{open}-caprolactone) nanoparticles for targeted delivery of tamoxifen in breast cancer. Int. J. Pharm. 2005, 293:261-270.
162. Kim S.Y., Lee Y.M. Taxol-loaded block copolymer nanospheres composed of methoxy poly(ethylene glycol) and poly(e{open}-caprolactone) as novel anticancer drug carriers. Biomaterials 2001, 22:1697-1704.
163. Zheng D., Li X., Xu H., Lu X., Hu Y., Fan W. Study on docetaxel-loaded nanoparticles with high antitumor efficacy against malignant melanoma. Acta Biochim. Biophys. Sin. 2009, 41:578-587.
164. Prabu P., Chaudhari A.A., Dharmaraj N., Khil M.S., Park S.Y., Kim H.Y. Preparation, characterization, in-vitro drug release and cellular uptake of poly(caprolactone) grafted dextran copolymeric nanoparticles loaded with anticancer drug. J. Biomed. Mater. Res. A 2009, 90A:1128-1136.
165. Couvreur P., Couarraze G., Devissaguet J.P., Puisieux F. Nanoparticles: preparation and characterization. Microencapsulation: Methods and Industrial Application 1996, 183-211. Marcel Dekker, New York. S. Benita (Ed.).
166. Pinto Reis C., Neufeld R.J., Ribeiro A.J., Veiga F. Nanoencapsulation: I. Methods for preparation of drug-loaded polymeric nanoparticles. Nanomedicine 2006, 2:8-21.
167. Allemann E., Gurny R., Doelker E. Drug-loaded nanoparticles - preparation methods and drug targeting issues. Eur. J. Pharm. Biopharm. 1993, 39:173-191.
168. Fonseca C., Simões S., Gaspar R. Paclitaxel-loaded PLGA nanoparticles: preparation, physicochemical characterization and in vitro anti-tumoral activity. J. Control. Release 2002, 83:273-286.
169. Nanda R., Sasmal A., Nayak P.L. Preparation and characterization of chitosan-polylactide composites blended with Cloisite 30B for control release of the anticancer drug paclitaxel. Carbohydr. Polym. 2011, 83:988-994.
170. Iqbal J., Sarti F., Perera G., Bernkop-Schnürch A. Development and in vivo evaluation of an oral drug delivery system for paclitaxel. Biomaterials 2011, 32:170-175.
171. Brown L.R. Commercial challenges of protein drug delivery. Expert Opin. Drug Deliv. 2005, 2:29-42.
172. Reis C.P. Micro e Nanopartículas Biomacromoleculares. Novas Formas Farmacêuticas para Administração de Fármacos, edições 2011, 199-236. Universidade Fernando Pessoa, Porto. E.B. Souto, C.M. Lopes (Eds.).
173. Shechter Y., Mironchik M., Rubinraut S., Saul A., Tsubery H., Fridkin M. Albumin-insulin conjugate releasing insulin slowly under physiological conditions: a new concept for long-acting insulin. Bioconjug. Chem. 2005, 16:913-920.
174. Rhaese S., von Briesen H., Rübsamen-Waigmann H., Kreuter J., Langer K. Human serum albumin-polyethylenimine nanoparticles for gene delivery. J. Control. Release 2003, 92:199-208.
175. Orson F., Kinsey B., Bhogal B., Song L., Densmore C., Barry M. Targeted delivery of expression plasmids to the lung via macroaggregated polyethylenimine-albumin conjugates. Lung Cancer 2003, 575-590. Humana Press. B. Driscoll (Ed.).
176. Patil G.V. Biopolymer albumin for diagnosis and in drug delivery. Drug Dev. Res. 2003, 58:219-247.
177. Tuan Giam Chuang V., Kragh-Hansen U., Otagiri M. Pharmaceutical strategies utilizing recombinant human serum albumin. Pharm. Res. 2002, 19:569-577.
178. Elsadek B., Kratz F. Impact of albumin on drug delivery - new applications on the horizon. J. Control. Release 2012, 157:4-28.
179. Park K. Albumin: a versatile carrier for drug delivery. J. Control. Release 2012, 157:3.
180. Elzoghby A.O., Samy W.M., Elgindy N.A. Albumin-based nanoparticles as potential controlled release drug delivery systems. J. Control. Release 2012, 157:168-182.
181. Sharma R.I., Pereira M., Schwarzbauer J.E., Moghe P.V. Albumin-derived nanocarriers: substrates for enhanced cell adhesive ligand display and cell motility. Biomaterials 2006, 27:3589-3598.
182. Roser M., Fischer D., Kissel T. Surface-modified biodegradable albumin nano- and microspheres. II: Effect of surface charges on in vitro phagocytosis and biodistribution in rats. Eur. J. Pharm. Biopharm. 1998, 46:255-263.
183. Kratz F. Albumin as a drug carrier: design of prodrugs, drug conjugates and nanoparticles. J. Control. Release 2008, 132:171-183.
184. Dreis S., Rothweiler F., Michaelis M., Cinatl J., Kreuter J., Langer K. Preparation, characterisation and maintenance of drug efficacy of doxorubicin-loaded human serum albumin (HSA) nanoparticles. Int. J. Pharm. 2007, 341:207-214.
185. Gradishar W.J., Tjulandin S., Davidson N., Shaw H., Desai N., Bhar P., Hawkins M., O'Shaughnessy J. Phase III trial of nanoparticle albumin-bound paclitaxel compared with polyethylated castor oil-based paclitaxel in women with breast cancer. J. Clin. Oncol. 2005, 23:7794-7803.
186. Gradishar W.J., Krasnojon D., Cheporov S., Makhson A.N., Manikhas G.M., Clawson A., Bhar P. Significantly longer progression-free survival with nab-paclitaxel compared with docetaxel as first-line therapy for metastatic breast cancer. J. Clin. Oncol. 2009, 27:3611-3619.
187. Schnitzer J.E. gp60 is an albumin-binding glycoprotein expressed by continuous endothelium involved in albumin transcytosis. Am. J. Physiol. Heart Circ. Physiol. 1992, 262:H246-H254.
188. Tiruppathi C., Song W., Bergenfeldt M., Sass P., Malik A.B. Gp60 activation mediates albumin transcytosis in endothelial cells by tyrosine kinase-dependent pathway. J. Biol. Chem. 1997, 272:25968-25975.
189. Wang Z., Tiruppathi C., Minshall R.D., Malik A.B. Size and dynamics of caveolae studied using nanoparticles in living endothelial cells. ACS Nano 2009, 3:4110-4116.
190. Lu Z., Yeh T.-K., Tsai M., Au J.L.-S., Wientjes M.G. Paclitaxel-loaded gelatin nanoparticles for intravesical bladder cancer therapy. Clin. Cancer Res. 2004, 10:7677-7684.
191. Livney Y.D. Milk proteins as vehicles for bioactives. Curr. Opin. Colloid Interface Sci. 2010, 15:73-83.
192. Horne D.S. Casein micelle structure: models and muddles. Curr. Opin. Colloid Interface Sci. 2006, 11:148-153.
193. Shapira A., Markman G., Assaraf Y.G., Livney Y.D. β-Casein-based nanovehicles for oral delivery of chemotherapeutic drugs: drug-protein interactions and mitoxantrone loading capacity. Nanomedicine 2010, 6:547-555.
194. Shapira A., Assaraf Y.G., Epstein D., Livney Y.D. Beta-casein nanoparticles as an oral delivery system for chemotherapeutic drugs: impact of drug structure and properties on co-assembly. Pharm. Res. 2010, 27:2175-2186.
195. Shapira A., Davidson I., Avni N., Assaraf Y.G., Livney Y.D. β-Casein nanoparticle-based oral drug delivery system for potential treatment of gastric carcinoma: stability, target-activated release and cytotoxicity. Eur. J. Pharm. Biopharm. 2012, 80:298-305.
196. Greco F., Vicent M.J. Combination therapy: opportunities and challenges for polymer-drug conjugates as anticancer nanomedicines. Adv. Drug Deliv. Rev. 2009, 61:1203-1213.
197. Lv S., Tang Z., Zhang D., Song W., Li M., Lin J., Liu H., Chen X. Well-defined polymer-drug conjugate engineered with redox and pH-sensitive release mechanism for efficient delivery of paclitaxel. J. Control. Release 2014, 194:220-227.
198. Etrych T., Šubr V., Laga R., Říhová B., Ulbrich K. Polymer conjugates of doxorubicin bound through an amide and hydrazone bond: impact of the carrier structure onto synergistic action in the treatment of solid tumours. Eur. J. Pharm. Sci. 2014, 58:1-12.
199. Duangjai A., Luo K., Zhou Y., Yang J., Kopeček J. Combination cytotoxicity of backbone degradable HPMA copolymer gemcitabine and platinum conjugates toward human ovarian carcinoma cells. Eur. J. Pharm. Biopharm. 2014, 87:187-196.
200. Rowinsky E.K., Rizzo J., Ochoa L., Takimoto C.H., Forouzesh B., Schwartz G., Hammond L.A., Patnaik A., Kwiatek J., Goetz A., Denis L., McGuire J., Tolcher A.W. A phase I and pharmacokinetic study of pegylated camptothecin as a 1-hour infusion every 3 weeks in patients with advanced solid malignancies. J. Clin. Oncol. 2003, 21:148-157.
201. Ye H., Jin L., Hu R., Yi Z., Li J., Wu Y., Xi X., Wu Z. Poly(γ,l-glutamic acid)-cisplatin conjugate effectively inhibits human breast tumor xenografted in nude mice. Biomaterials. 2006, 27:5958-5965.
202. Plyduang T., Lomlim L., Yuenyongsawad S., Wiwattanapatapee R. Carboxymethylcellulose-tetrahydrocurcumin conjugates for colon-specific delivery of a novel anti-cancer agent, 4-amino tetrahydrocurcumin. Eur. J. Pharm. Biopharm. 2014, 88:351-360.
203. Khare V., Kour S., Alam N., Dubey R.D., Saneja A., Koul M., Gupta A.P., Singh D., Singh S.K., Saxena A.K., Gupta P.N. Synthesis, characterization and mechanistic-insight into the anti-proliferative potential of PLGA-gemcitabine conjugate. Int. J. Pharm. 2014, 470:51-62.
204. Maeda H. Polymer conjugated macromolecular drugs for tumor-specific targeting. Polymeric Site-specific Pharmacotherapy 1994, 95-116. John Wiley and Sons Ltd, USA. A.J. Domb (Ed.).
205. Vasey P.A., Kaye S.B., Morrison R., Twelves C., Wilson P., Duncan R., Thomson A.H., Murray L.S., Hilditch T.E., Murray T., Burtles S., Fraier D., Frigerio E., Cassidy J. Phase I clinical and pharmacokinetic study of PK1 [N-(2-hydroxypropyl)methacrylamide copolymer doxorubicin]: first member of a new class of chemotherapeutic agents - drug-polymer conjugates. Clin. Cancer Res. 1999, 5:83-94.
206. Meerum Terwogt J.M., Ten Bokkel Huinink W.W., Schellens J.H.M., Schot M., Mandjes I.A.M., Zurlo M.G., Rocchetti M., Rosing H., Koopman F.J., Beljnen J.H. Phase I clinical and pharmacokinetic study of PNU166945, a novel water-soluble polymer-conjugated prodrug of paclitaxel. Anti-cancer Drugs. 2001, 12:315-323.
207. Minko T., Kopečková P., Pozharov V., Kopeček J. HPMA copolymer bound adriamycin overcomes MDR1 gene encoded resistance in a human ovarian carcinoma cell line. J. Control. Release 1998, 54:223-233.
208. Říhová B., Strohalm J., Prausová J., Kubáčková K., Jelínková M., Rozprimová L., Šírová M., Plocová D., Etrych T., Šubr V., Mrkvan T., Kovář M., Ulbrich K. Cytostatic and immunomobilizing activities of polymer-bound drugs: experimental and first clinical data. J. Control. Release 2003, 91:1-16.
209. Sirova M., Strohalm J., Subr V., Plocova D., Rossmann P., Mrkvan T., Ulbrich K., Rihova B. Treatment with HPMA copolymer-based doxorubicin conjugate containing human immunoglobulin induces long-lasting systemic anti-tumour immunity in mice. Cancer Immunol. Immunother. 2007, 56:35-47.
210. Trail P.A., Willner D., Lasch S.J., Henderson A.J., Hofstead S., Casazza A.M., Firestone R.A., Hellström I., Hellström K.E. Cure of xenografted human carcinomas by BR96-doxorubicin immunoconjugates. Science 1993, 261:212-215.
211. Trail P.A., Willner D., Hellstrom K.E. Site-directed delivery of anthracyclines for treatment of cancer. Drug Dev. Res. 1995, 34:196-209.
212. Sjögren H.O., Isaksson M., Willner D., Hellström I., Hellström K.E., Trail P.A. Antitumor activity of carcinoma-reactive BR96-doxorubicin conjugate against human carcinomas in athymic mice and rats and syngeneic rat carcinomas in immunecompetent rats. Cancer Res. 1997, 57:4530-4536.
213. Tolcher A.W., Sugarman S., Gelmon K.A., Cohen R., Saleh M., Isaacs C., Young L., Healey D., Onetto N., Slichenmyer W. Randomized phase II study of BR96-doxorubicin conjugate in patients with metastatic breast cancer. J. Clin. Oncol. 1999, 17:478-484.
214. Saleh M.N., LoBuglio A.F., Trail P.A. Immunoconjugate therapy of solid tumors: studies with BR96-doxorubicin. Monoclonal Antibody-Based Therapy of Cancer 1998, 397-416. Marcel Dekker, New York. M. Grossbard (Ed.).
215. Danhier F., Feron O., Préat V. To exploit the tumor microenvironment: passive and active tumor targeting of nanocarriers for anti-cancer drug delivery. J. Control. Release 2010, 148:135-146.
216. Bae Y.H. Drug targeting and tumor heterogeneity. J. Control. Release 2009, 133:2-3.
217. Daniels T.R., Delgado T., Helguera G., Penichet M.L. The transferrin receptor. Part II: Targeted delivery of therapeutic agents into cancer cells. Clin. Immunol. 2006, 121:159-176.
218. Low P.S., Kularatne S.A. Folate-targeted therapeutic and imaging agents for cancer. Curr. Opin. Chem. Biol. 2009, 13:256-262.
219. Minko T. Drug targeting to the colon with lectins and neoglycoconjugates. Adv. Drug Deliv. Rev. 2004, 56:491-509.
220. Doane T.L., Burda C. The unique role of nanoparticles in nanomedicine: imaging, drug delivery and therapy. Chem. Soc. Rev. 2012, 41:2885-2911.
221. Brigger I., Dubernet C., Couvreur P. Nanoparticles in cancer therapy and diagnosis. Adv. Drug Deliv. Rev. 2012, 64(Supplement):24-36.
222. Yang K., Feng L., Shi X., Liu Z. Nano-graphene in biomedicine: theranostic applications. Chem. Soc. Rev. 2013, 42:530-547.
223. Tian G., Zheng X., Zhang X., Yin W., Yu J., Wang D., Zhang Z., Yang X., Gu Z., Zhao Y. TPGS-stabilized NaYbF4:Er upconversion nanoparticles for dual-modal fluorescent/CT imaging and anticancer drug delivery to overcome multi-drug resistance. Biomaterials 2015, 40:107-116.
224. Petersen A.L., Hansen A.E., Gabizon A., Andresen T.L. Liposome imaging agents in personalized medicine. Adv. Drug Deliv. Rev. 2012, 64:1417-1435.
225. Kievit F.M., Zhang M. Cancer nanotheranostics: improving imaging and therapy by targeted delivery across biological barriers. Adv. Mater. (Deerfield Beach Fla.) 2011, 23:H217-H247.
226. Chen X., Gambhir S.S., Cheon J. Theranostic nanomedicine. Acc Chem. Res. 2011, 44:841.
227. Sumer B., Gao J. Theranostic nanomedicine for cancer. Nanomedicine 2008, 3:137-140.
228. Lammers T., Kiessling F., Hennink W.E., Storm G. Nanotheranostics and image-guided drug delivery: current concepts and future directions. Mol. Pharm. 2010, 7:1899-1912.
229. Di W., Ren X., Zhao H., Shirahata N., Sakka Y., Qin W. Single-phased luminescent mesoporous nanoparticles for simultaneous cell imaging and anticancer drug delivery. Biomaterials 2011, 32:7226-7233.
230. Ye F., Barrefelt Å., Asem H., Abedi-Valugerdi M., El-Serafi I., Saghafian M., Abu-Salah K., Alrokayan S., Muhammed M., Hassan M. Biodegradable polymeric vesicles containing magnetic nanoparticles, quantum dots and anticancer drugs for drug delivery and imaging. Biomaterials 2014, 35:3885-3894.
231. Jun Y.-W., Lee J.-H., Cheon J. Chemical design of nanoparticle probes for high-performance magnetic resonance imaging. Angew. Chem. Int. Ed. 2008, 47:5122-5135.
232. Resch-Genger U., Grabolle M., Cavaliere-Jaricot S., Nitschke R., Nann T. Quantum dots versus organic dyes as fluorescent labels. Nat. Meth. 2008, 5:763-775.
233. ®-The first FDA-approved nano-drug: lessons learned. J. Control. Release 2012, 160:117-134.
234. Svenson S. What nanomedicine in the clinic right now really forms nanoparticles?. Wiley Interdiscip. Rev. Nanomed. Nanobiotechnol. 2014, 6:125-135.
235. Muggia F.M. Liposomal encapsulated anthracyclines: new therapeutic horizons. Curr. Oncol. Rep. 2001, 3:156-162.
236. Hamaguchi T., Matsumura Y., Nakanishi Y., Muro K., Yamada Y., Shimada Y., Shirao K., Niki H., Hosokawa S., Tagawa T., Kakizoe T. Antitumor effect of MCC-465, pegylated liposomal doxorubicin tagged with newly developed monoclonal antibody GAH, in colorectal cancer xenografts. Cancer Sci. 2004, 95:608-613.
237. Matsumura Y., Gotoh M., Muro K., Yamada Y., Shirao K., Shimada Y., Okuwa M., Matsumoto S., Miyata Y., Ohkura H., Chin K., Baba S., Yamao T., Kannami A., Takamatsu Y., Ito K., Takahashi K. Phase I and pharmacokinetic study of MCC-465, a doxorubicin (DXR) encapsulated in PEG immunoliposome, in patients with metastatic stomach cancer. Ann. Oncol. 2004, 15:517-525.
238. THERMODOX®. Celsion Corporation. Available from: (accessed 18.11.14). http://celsion.com/docs/technology_thermodox.
239. DaunoXome® (liposomal daunorubicin). Galen - Advanced Human Health, United Kingdom, 2013. Available from: (accessed 21.11.14). http://www.galen.co.uk/products/daunoxome.
240. Drugs at FDA FDA - U.S. Food and Drug Administration USA 2014, Available from: http://www.accessdata.fda.gov/drugsatfda_docs/label/2012/202497s000lbl.pdf (accessed 21.11.14).
241. DepoCyte®. EMA - European Medicines Agency, 2012. Available from: (accessed 21.11.14). http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/000317/human_med_000740.jsp%26mid=WC0b01ac058001d124.
242. CPX-351 and Acute Myeloid Leukemia Celator Pharmaceuticals 2014, Available from: http://www.celatorpharma.com/new/products_cpx351.html (accessed 21.11.14).
243. Wheate N.J., Walker S., Craig G.E., Oun R. The status of platinum anticancer drugs in the clinic and in clinical trials. Dalton Trans. 2010, 39:8113-8127.
244. Product/Pipeline - Active Targeting Drug Delivery System Mebiopharm Co., Ltd. 2011, Available from: http://www.mebiopharm.com/english/pro.html (accessed 21.11.14).
245. Wetzler M., Thomas D.A., Wang E.S., Shepard R., Ford L.A., Heffner T.L., Parekh S., Andreeff M., O'Brien S., Kantarjian H.M. Phase I/II trial of nanomolecular liposomal annamycin in adult patients with relapsed/refractory acute lymphoblastic leukemia. Clin. Lymphoma Myeloma Leuk. 2013, 13:430-434.
246. Azaya therapeutics - products pipeline Azaya Therapeutics 2014, Available from: http://www.mebiopharm.com/english/pro.html (accessed 21.11.14).
247. Allen T.M., Cullis P.R. Liposomal drug delivery systems: from concept to clinical applications. Adv. Drug Deliv. Rev. 2013, 65:36-48.
248. CPX-1 and Colorectal Cancer Celator Pharmaceuticals 2014, Available from: http://www.celatorpharma.com/new/products_CPX1.html (accessed 22.11.14).
249. Pipeline - Lipotecan®. Taiwan Liposome Company, 2013. Available from: (accessed 21.11.14). http://www.tlcbio.com/en-global/pipeline/202.
250. Safety Study of Infusion of SGT-53 to Treat Solid Tumors Clinical Trials Search 2014, Available from: http://www.clinicaltrialssearch.org/safety-study-of-infusion-of-sgt-53-to-treat-solid-tumors-nct00470613.html (accessed 22.11.14).
251. Pipeline Products Tekmira Pharmaceuticals Corporation 2014, Available from: http://www.supratek.com/pipeline (accessed 22.11.14).
252. Gene Therapy in Treating Patients With Advanced Head and Neck Cancer. National Cancer Institute 2014, Available from: http://www.cancer.gov/clinicaltrials/search/view?cdrid=68414&version=HealthProfessional (accessed 22.11.14).
253. Ahn H., Jung M., Sym S., Shin D., Kang S., Kyung S., Park J.-W., Jeong S., Cho E. A phase II trial of Cremorphor EL-free paclitaxel (Genexol-PM) and gemcitabine in patients with advanced non-small cell lung cancer. Cancer Chemother. Pharmacol. 2014, 74:277-282.
254. NanoCarrier® - Research and Development - Pipeline. NanoCarrier® - Leading Edge Nanotechnology, 2013. Available from: (accessed 21.11.14). http://www.nanocarrier.co.jp/en/research/pipeline/index.html.
255. Cabral H., Kataoka K. Progress of drug-loaded polymeric micelles into clinical studies. J. Control. Release 2014, 190:465-476.
256. Pipeline Supreatek Pharma Inc. 2014, Available from: http://www.supratek.com/pipeline (accessed 22.11.14).
257. Dendrimer Drug Delivery (DEP™). Starpharma, 2014. Available from: (accessed 21.11.14). http://www.starpharma.com/drug_delivery.
258. CALAA-01 Pipeline. Arrowhead Research Corporation. Available from: (accessed 23.11.14). http://www.arrowheadresearch.com/programs/calaa-01.
259. Vishnu P., Roy V. Safety and efficacy of nab-paclitaxel in the treatment of patients with breast cancer. Breast Cancer (Auckl.) 2011, 5:53-65.
260. Desai N. Nanoparticle albumin bound (nab) technology: targeting tumors through the endothelial gp60 receptor and SPARC. Nanomedicine 2007, 3:339.
261. Orphan Oncology Products Onxeo 2014, Available from: http://www.onxeo.com/en/nos-produits/portefeuilles-produits/orphelins-oncologie/ (accessed 22.11.14).
262. Paclitaxel or Polyglutamate Paclitaxel or Observation in Treating Patients With Stage III or Stage IV Ovarian Epithelial or Peritoneal Cancer or Fallopian Tube Cancer. cti Biopharma, 2014. Available from: (accessed 22.11.14). http://www.ctibiopharma.com/clinical-trials/trials-compound/.
263. FDA Approves pegaspargase (Oncaspar, Enzon Pharmaceuticals, Inc.) for the first-line treatment of patients with acute lymphoblastic leukemia FDA - U.S. Food and Drug Administration 2006, Available from: http://www.fda.gov/AboutFDA/CentersOffices/OfficeofMedicalProductsandTobacco/CDER/ucm095609.htm (accessed 22.11.14).
264. Seymour L.W., Ferry D.R., Kerr D.J., Rea D., Whitlock M., Poyner R., Boivin C., Hesslewood S., Twelves C., Blackie R., Schatzlein A., Jodrell D., Bissett D., Calvert H., Lind M., Robbins A., Burtles S., Duncan R., Cassidy J. Phase II studies of polymer-doxorubicin (PK1, FCE28068) in the treatment of breast, lung and colorectal cancer. Int. J. Oncol. 2009, 34:1629-1636.
265. Seymour L.W., Ferry D.R., Anderson D., Hesslewood S., Julyan P.J., Poyner R., Doran J., Young A.M., Burtles S., Kerr D.J. Hepatic drug targeting: phase I evaluation of polymer-bound doxorubicin. J. Clin. Oncol. 2002, 20:1668-1676.
266. Yurkovetskiy A.V., Fram R.J. XMT-1001, a novel polymeric camptothecin pro-drug in clinical development for patients with advanced cancer. Adv. Drug Deliv. Rev. 2009, 61:1193-1202.
267. Bissett D., Cassidy J., de Bono J.S., Muirhead F., Main M., Robson L., Fraier D., Magne M.L., Pellizzoni C., Porro M.G., Spinelli R., Speed W., Twelves C. Phase I and pharmacokinetic (PK) study of MAG-CPT (PNU 166148): a polymeric derivative of camptothecin (CPT). Br. J. Cancer. 2004, 91:50-55.
268. Soepenberg O., de Jonge M.J.A., Sparreboom A., de Bruin P., Eskens F.A.L.M., de Heus G., Wanders J., Cheverton P., Ducharme M.P., Verweij J. Phase I and pharmacokinetic study of DE-310 in patients with advanced solid tumors. Clin. Cancer Res. 2005, 11:703-711.
269. NKTR-105 Demonstrates Superior Antitumor Activity and Improved Pharmacokinetics Over Docetaxel in Preclinical Studies Presented at AACR. Nektar Therap. 2009, Available from: http://ir.nektar.com/releasedetail.cfm?releaseid=378943 (accessed 22.11.14).